CS1，一种参与免疫调节的 SLAM 家族受体，是多发性骨髓瘤的治疗靶点。
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
机构信息
Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada H2W 1R7; Department of Medicine, McGill University, Montréal, Québec, Canada H3G 1Y6; Department of Medicine, University of Montréal, Montréal, Québec, Canada H3T 1J4.
出版信息
Crit Rev Oncol Hematol. 2013 Oct;88(1):168-77. doi: 10.1016/j.critrevonc.2013.04.003. Epub 2013 Jun 2.
Signaling lymphocytic activation molecule (SLAM) family receptors have been implicated in normal immunity, immunodeficiencies and autoimmunity. CS1 (also known as CRACC, CD319 and SLAMF7) is a member of the SLAM family expressed on several normal hematopoietic cell types. It is also highly and nearly universally expressed on multiple myeloma (MM) cells. This review focuses on the biology of CS1, both in normal hematopoietic cells and in MM cells. It also discusses the preclinical and clinical data on the use of a humanized anti-CS1 monoclonal antibody, elotuzumab, for the treatment of MM. Based on current knowledge, CS1 is a compelling new target for the treatment of MM.
信号淋巴细胞激活分子（SLAM）家族受体与正常免疫、免疫缺陷和自身免疫有关。CS1（也称为 CRACC、CD319 和 SLAMF7）是 SLAM 家族的成员，在几种正常造血细胞类型上表达。它也在多发性骨髓瘤（MM）细胞上高度且几乎普遍表达。本综述重点介绍 CS1 的生物学特性，包括在正常造血细胞和 MM 细胞中的生物学特性。它还讨论了使用人源化抗 CS1 单克隆抗体依鲁替尼治疗 MM 的临床前和临床数据。基于目前的知识，CS1 是治疗 MM 的一个有吸引力的新靶点。
Zotero 插件